Argenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
Argenx has been collaborating with Unnatural Products in drug discovery for more than a year. The companies have yet to report the progress of this research, but what Argenx has…
TR
By Tom Reyes · Markets Editor
Nov 9 16:45 ETSource: MedCity News
From the source
Read at medcitynews.comArgenx Adds Oral Peptides to Its Immunology Strategy With $550M UNP Acquisition
Argenx has been collaborating with Unnatural Products in drug discovery for more than a year. The companies have yet to report the progress of this research, but what Argenx has seen about its partner’s platform technology so far has persuaded it to buy the startup outright for $550 million up front .
